| 摘要 |
PROBLEM TO BE SOLVED: To provide novel utility of a pharmaceutical composition containing an ACE inhibitor such as enalapril as an effective component for treating central nervous system demyelinating autoimmune diseases such as multiple sclerosis (MS) as well as usage and dosage thereof by clarifying involvement of bradykinin in the EAE pathological conditions. ! SOLUTION: Low dose administration of enalapril, an ACE inhibitor, increases the serum concentration of bradykinin, which lowers the invasion of interleukin-17 positive cells into the central nervous system and improves clinical and pathological severity of EAE such as demyelination and inflammatory index. As the invention recognizes, a remarkable improving effects on the central nervous system demyelinating autoimmune diseases at a dose as low as 1/100 to 1/10 of the dosage used for hypertension treatment without side effects recognized in the application in the field of circulatory organs as well as new application as the central nervous system |
